Abstract
We investigated a curve-fitting method for the rate of blood retention of99mTc-galactosyl serum albumin (GSA) as a substitute for the blood sampling method. Seven healthy volunteers and 27 patients with liver disease underwent99mTc-GSA scanning. After normalization of they-intercept as 100 percent, a biexponential regression curve for the precordial time-activity curve provided the percent injected dose (%ID) of99mTc-GSA in the blood without blood sampling. The discrepancy between %ID obtained by the curve-fitting method and that by the multiple blood samples was minimal in normal volunteers 3.1 ± 2.1% (mean ± standard deviation, n = 77 sampling). Slightly greater discrepancy was observed in patients with liver disease (7.5 ± 6.1%, n = 135 sampling). The %ID at 15 min after injection obtained from the fitted curve was significantly greater in patients with liver cirrhosis than in the controls (53.2 ± 11.6%, n = 13; vs. 31.9 ± 2.8%, n = 7, p < 0.0001). There was a highly linear correlation between the %IDs of99mTc-GSA and the plasma retention rate for indocyanine green (r = − 0.869, p < 0.0001, n = 27). These results indicate that the curve-fitting method provides an accurate %ID of99mTc-GSA and could be a substitute for the blood sampling method.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Morell AG, Irvine RA, Sternlieb I, Scheunberg IH, Ashwell G. Physical and chemical studies on ceruloplasmin. V. Metabolic studies on sialic acid-free ceruloplasminin vivo.J Biol Chem 243: 155–159, 1968.
Ashwell G, Morell AG. The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins.Adv Enzymol 41: 99–128, 1974.
Pricer WE, Ashwell G. The binding of desialylated glycoproteins by plasma membranes of liver.J Biol Chem 246: 4825–4833, 1971.
Stockert RJ, Becker FF. Diminished hepatic binding protein for desialylated glycoproteins during chemical hepatocarcinogenesis.Cancer Res 40: 3632–3634, 1980.
Sawamura T, Kawasato S, Shiozaki Y, Samesima Y, Nakada H, Tashiro Y. Decrease of a hepatic binding protein specific for asialoglycoproteins with accumulation of serum asialoglycoproteins in galactosamine-treated rats.Gastroenterology 81: 527–533, 1981.
Sawamura T, Nakada H, Hazama Y, Shiozaki Y, Samesima Y, Tashiro Y. Hyperasialoglycoproteinemia in patients with chronic liver diseases and/or liver cell carcinoma.Gastroenterology 87: 1217–1221, 1984.
Stadalnik RC, Vera DR, Woodle ES, Trudeau WL, Porter BA, Ward RE, et al. Technetium-99m NGA functional hepatic imaging: preliminary clinical experience.J Nucl Med 26: 1233–1242, 1985.
Kawa S, Hazama H, Kojima M, Nishiyama Y, Nakazawa M, Hasegawa T, et al. A new liver function test using the asialoglycoprotein-receptor system on the liver cell membrane: II. Quantitative evaluation of labeled neoglycoprotein clearance.KAKU IGAKU (Jpn J Nucl Med) 23: 907–916, 1986 (in Japanese).
Galli G, Maini CL, Orlando P, Cobelli C, Thomaset K, Deleide G, et al. A radiopharmaceutical for the study of the liver:99mTc-DTPA-asialo-orosomucoid. II: Human dynamic and imaging studies.J Nucl Med Allied Sci 32: 117–126, 1988.
Bossuyt A, De Geeter F, Jacobs A, Camus M, Thornback JR. Initial clinical experience with a new kit formulation of Tc-99m-b galactosylated albumin for functional hepatic imaging.Nucl Med Comm 11: 469–475, 1990.
Ha-Kawa SK, Tanaka Y. A quantitative model of technetium-99m-DTPA-galactosyl-HSA for the assessment of hepatic blood flow and hepatic binding receptor.J Nucl Med 32:2233–2240, 1991.
Kubota Y, Kojima M, Hazama H, Kawa S, Nakazawa M, Nishiyama Y, et al. A new liver function test using the asialoglycoprotein-receptor system on the liver cell membrane: I. Evaluation of liver imaging using the Tc-99m-neoglycoprotein.KAKU IGAKU (Jpn J Nucl Med) 23: 899–905, 1986 (in Japanese).
Hazama H, Kawa S, Kubota Y, Kojima M, Murase T, Okuno H, et al. A new liver function test using the asialoglycoprotein-receptor system on the liver cell membrane: III. Evaluation for usefulness by liver function test using the Tc-99m-neoglycoprotein.KAKU IGAKU (Jpn J Nucl Med) 23: 917–926, 1986 (in Japanese).
Torizuka K, Ha-Kawa SK, Ikekubo K, Suga Y, Tanaka Y, Hino M, et al. Phase I clinical study on99mTc-GSA, a new agent for functional imaging of the liver.KAKU IGAKU (Jpn J Nucl Med) 28: 1321–1331, 1991 (in Japanese).
Torizuka K, Ha-Kawa SK, Kudo M, Kitagawa S, Kubota Y, Tanaka Y, et al. Phase II clinical study on99mTc-GSA, a new agent for functional imaging of the liver.KAKU IGAKU (Jpn J Nucl Med) 29: 85–95, 1992 (in Japanese).
Torizuka K, Ha-Kawa SK, Kudo M, Kubota Y, Yamamoto K, Itoh K, et al. Phase III Multi-center clinical study on99mTc-GSA, a new agent for functional imaging of the liver.KAKU IGAKU (Jpn J Nucl Med) 29: 159–181, 1992 (in Japanese).
Fujita T. The measurement of circulating blood volume.Respiration and Circulation 18: 13–24, 1970 (in Japanese).
Lieberman FL, Reynolds TB. Plasma volume in cirrhosis of the liver: Its relation to portal hypertension, ascites, and renal failure.J Clin Invest 46: 1297–1308, 1967.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ha-Kawa, S.K., Suga, Y., Kouda, K. et al. Validation of curve-fitting method for blood retention of99mTc-GSA: Comparison with blood sampling method. Ann Nucl Med 11, 15–20 (1997). https://doi.org/10.1007/BF03164752
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF03164752